{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:14:12Z","timestamp":1794924852657,"version":"4.9.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review provides a timely synthesis of key findings derived from the EUSTAR (European Scleroderma Trials and Research) database, the largest international registry dedicated to systemic sclerosis (SSc), now including over 27 000 patients worldwide. As interest grows in real-world data and precision medicine in rare diseases, EUSTAR offers a uniquely rich, longitudinal dataset built over two decades of global collaboration. With sustained growth, more than 1000 new patients enrolled annually, this registry continues to inform clinical practice and research with contemporary, diverse patient data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Analyses from EUSTAR have clarified disease phenotypes and trajectories, identified predictors of organ involvement and mortality, and validated outcome measures including the EUSTAR Activity Index. Studies have also revealed heterogeneity in treatment patterns, supported the refinement of classification criteria, and highlighted regional disparities in care. The registry has been a foundation for innovative research approaches such as emulated clinical trials, comparative effectiveness analyses, and external control arms for interventional studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>EUSTAR has become a reference model for collaborative research in rare diseases. Its findings have directly informed guidelines and routine management of SSc. Future directions include integrating digital tools, artificial intelligence, and expanding the registry's role in clinical trial design and personalized medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001128","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:06:22Z","timestamp":1758207982000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["What have we learned about systemic sclerosis from the EUSTAR database?"],"prefix":"10.1097","volume":"38","author":[{"given":"Corrado","family":"Campochiaro","sequence":"first","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases. San Raffaele Hospital. and Vita-Salute San Raffaele University, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon C.","family":"Vonk","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Department of Rheumatology; Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Osborne","sequence":"additional","affiliation":[{"name":"Leeds Raynaud's and Scleroderma Program, NIHR Biomedical Research Centre Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Lazzaroni","sequence":"additional","affiliation":[{"name":"Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Santiago","sequence":"additional","affiliation":[{"name":"Centro Hospital e Universit\u00e1rio de Coimbra, University of Coimbra, Coimbra, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Raynaud's and Scleroderma Program, NIHR Biomedical Research Centre Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Rheumatology Department, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"keaf264","DOI":"10.1093\/rheumatology\/keaf264","article-title":"Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study","volume":"64","author":"Sobanski","year":"2025","journal-title":"Rheumatology"},{"key":"R4-20251204","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"key":"R5-20251204","doi-asserted-by":"crossref","first-page":"keaf016","DOI":"10.1093\/rheumatology\/keaf016","article-title":"Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort","volume":"64","author":"Roth","year":"2025","journal-title":"Rheumatology"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/rheumatology\/keac660","article-title":"Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis","volume":"62","author":"Campochiaro","year":"2023","journal-title":"Rheumatology"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ard.2025.01.014","article-title":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database","volume":"84","author":"Yan","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R8-20251204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","article-title":"Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group","volume":"20","author":"Adler","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","article-title":"Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European Scleroderma Trials and Research","volume":"163","author":"Hoffmann-Vold","year":"2023","journal-title":"Chest"},{"key":"R10-20251204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13075-019-1822-1","article-title":"Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher\/European Scleroderma Trials and Research group (EUSTAR) survey","volume":"21","author":"Blagojevic","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/kez558","article-title":"Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort","volume":"59","author":"Mihai","year":"2020","journal-title":"Rheumatology"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"keaf290","DOI":"10.1093\/rheumatology\/keaf290","article-title":"Temporal trends in vascular medication use in 8,079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort","volume":"64","author":"Di Donato","year":"2025","journal-title":"Rheumatol Oxf Engl"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1093\/rheumatology\/keaf053","article-title":"A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis","volume":"64","author":"Bj\u00f8rkekj\u00e6r","year":"2025","journal-title":"Rheumatology"},{"key":"R14-20251204","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.chest.2024.05.010","article-title":"Diffusing capacity of the lungs for carbon monoxide and echocardiographic parameters in identifying mild pulmonary hypertension in the EUSTAR cohort of patients with systemic sclerosis","volume":"166","author":"Colalillo","year":"2024","journal-title":"Chest"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"(SI)","key":"R16-20251204","doi-asserted-by":"crossref","first-page":"SI54","DOI":"10.1093\/rheumatology\/keac363","article-title":"Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort","volume":"62","author":"Hughes","year":"2023","journal-title":"Rheumatology"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/annrheumdis-2015-208024","article-title":"Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis","volume":"75","author":"Dobrota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R18-20251204","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","article-title":"Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database","volume":"75","author":"Wirz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/annrheumdis-2019-215787","article-title":"Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual","volume":"78","author":"Fasano","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"e036730","DOI":"10.1161\/JAHA.124.036730","article-title":"Evaluation of systemic sclerosis primary heart involvement and chronic heart failure in the European Scleroderma Trials and Research Cohort","volume":"14","author":"Gy\u00f6rfi","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R23-20251204","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/rheumatology\/ker110","article-title":"Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study","volume":"50","author":"Wipff","year":"2011","journal-title":"Rheumatology"},{"key":"R24-20251204","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2020-217035","article-title":"Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"79","author":"Hughes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"e002477","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R27-20251204","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience","volume":"50","author":"Castellv\u00ed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keab437","article-title":"Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database","volume":"61","author":"Iudici","year":"2022","journal-title":"Rheumatology"},{"key":"R30-20251204","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R31-20251204","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/S2665-9913(22)00224-7","article-title":"Sex-specific risk of antitopoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts","volume":"4","author":"Liem","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R32-20251204","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive antitopoisomerase I antibodies: data from the EUSTAR cohort","author":"Zanatta"},{"key":"R33-20251204","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: results from the EUSTAR cohort","volume":"60","author":"Lazzaroni","year":"2021","journal-title":"Rheumatology"},{"key":"R34-20251204","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multicentre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R35-20251204","first-page":"23971983251324827","article-title":"Interstitial lung disease in anti-U1RNP systemic sclerosis patients: a European Scleroderma Trials and Research analysis","volume":"10","author":"Campochiaro","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"R36-20251204","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2024.03.035","article-title":"Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review","volume":"125","author":"Dima","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R37-20251204","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R38-20251204","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R39-20251204","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/ard.2010.144360","article-title":"Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres","volume":"70","author":"Fransen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R40-20251204","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R41-20251204","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:00:50Z","timestamp":1764860450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001128","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}